FAQ / TERMS AND LIMITS
Questions Worth Asking Before the Claim
Plain answers, source numbers, and clear boundaries between literature, paperwork, and sample identity.
What does a GHK-Cu peptide do?
In laboratory and topical research, GHK-Cu is associated with copper transport, collagen and matrix signaling, and tissue-remodeling pathways [4][6][7]. Small human topical studies report skin-related outcomes, while broad systemic or “anti-aging” claims go beyond the strongest evidence [1][3]. A sample still requires independent identity work.
What is the difference between GHK and GHK-Cu?
GHK is the free three-amino-acid peptide. GHK-Cu is the peptide coordinated to copper(II). Much reported remodeling activity concerns the copper-bound form [1][4]. A label or total-copper value alone may not establish that intact complex, so the chemical form belongs in both the analytical question and custody record.
Is GHK-Cu peptide really anti-aging?
“Anti-aging” is too broad for the evidence. Reviews summarize small topical studies involving collagen and visible skin measures, and laboratory work reports repair-related signaling [1][2][4]. Those findings do not establish whole-body age reversal, systemic benefit, or equivalence among preparations. The narrow topical claim is better supported than the sweeping phrase.
What does BPC-157 do in the body?
Most answers come from animals and cells. BPC-157 is linked to VEGFR2-driven blood-vessel signaling and tissue-protection effects in experimental injury models [11][12]. Human evidence remains extremely limited, with only a tiny safety pilot and a few pilot reports summarized in a recent review [8][9]. Human benefit is therefore unproven.
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic fifteen-amino-acid research peptide, not growth hormone [11]. Some laboratory work discusses growth-related signaling, but its best-characterized pathway involves VEGFR2, Akt, and nitric-oxide signaling [11]. Related pathway language does not make two molecules identical or give them the same evidence base.
Does BPC-157 work immediately?
The published corpus does not establish an immediate human therapeutic effect. Animal studies measured outcomes within their own protocols, and pharmacokinetic work in rats and dogs found rapid breakdown [10][12]. Those timings cannot become a human expectation. Informal reports are uncontrolled and may involve materials whose identity was never independently verified.
Does BPC-157 damage the liver?
The available human record is too small to define uncommon or long-term liver risk. A two-person pilot reported no measured hepatic biomarker change, but that sample cannot settle safety [8]. Reviews emphasize that rigorous large studies are absent [9]. Lack of a signal in two participants is not evidence that liver injury cannot occur.
What is tirzepatide?
Tirzepatide is an approved prescription peptide medicine that activates both GIP and GLP-1 receptors [14]. It has large clinical trials in type 2 diabetes and obesity-related settings [13][16][17]. That evidence belongs to regulated formulations and does not authenticate independently supplied material carrying the same name.
How does tirzepatide work?
It increases glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying, and reduces appetite through dual GIP and GLP-1 receptor activity [14]. Clinical trials confirm effects on glycated hemoglobin and body weight [16][17]. Receptor mechanism explains plausibility; trials establish outcomes; neither replaces lot-specific identity testing.
What is ipamorelin?
Ipamorelin is a five-amino-acid agonist of the ghrelin receptor and a growth-hormone secretagogue [21]. Small human studies measured a brief growth-hormone pulse and pharmacokinetics [21]. It has no approved human indication, and its principal published clinical trial did not meet the primary efficacy endpoint [20].
What does ipamorelin do for a person?
The controlled human evidence supports an acute growth-hormone response, not the broad recovery, sleep, or body-composition promises common in informal discussion [21]. A postoperative trial failed to show a statistically significant improvement in its main endpoint [20]. Animal findings on weight and bone growth should remain labeled by species [18][22].
What are the risks of ipamorelin?
Long-term human safety is unknown. Growth-hormone-axis effects create mechanism-based concerns, and a different agonist at the same receptor caused heart-muscle injury in a rat study [19]. That is an indirect class signal, not proof of the same harm from ipamorelin. Unapproved supply also adds identity, purity, and sterility uncertainty.